, Volume 182, Issue 3–4, pp 379–385 | Cite as

Aspergillus flavus Keratitis: Experience of a Tertiary Eye Clinic in Turkey

  • Elif Erdem
  • Meltem Yagmur
  • Hazal Boral
  • Macit Ilkit
  • Reha Ersoz
  • Seyedmojtaba Seyedmousavi


We investigated the clinical and mycological characteristics of four cases of mycotic keratitis caused by Aspergillus flavus that occurred from July 2014 to May 2015 at Çukurova University Hospital, Adana, Turkey. In a 10-month period, a total of 64 corneal smear/scrapings were examined from patients with suspected mycotic keratitis. Fungal cultures were positive in six of these patients, indicating a 9.4% incidence of mycotic keratitis in this region, including four cases of A. flavus and two cases of Fusarium spp. The predisposing factors, clinical presentation, and success of the therapeutic approaches were further evaluated. For all cases, topical voriconazole was the first choice of treatment. Surgical procedures were required to control infection in 3 of the 4 cases, including intrastromal voriconazole injection for two cases and keratoplasty for one case. Predisposing factors included trauma (two cases, 50%), contact lens use (one case, 25%), and previous ocular surgery (one case, 25%). The clinical presentations also differed, including a well-limited ulcer (one case), an ulcer with an irregular feathery margin (one case), and ulcers with satellite lesions (two cases). The mean duration between the time of presentation and definitive diagnosis by culture was 14 days (8–25 days). We observed that A. flavus keratitis can present with different underlying factors and clinical conditions. A combination of antifungal therapy and supportive surgical intervention may resolve infections caused by A. flavus in the cornea.


Aspergillus flavus Mycotic keratitis Voriconazole 


Compliance with Ethical Standards

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.


  1. 1.
    Manikandan P, Varga J, Kocsube S, et al. Epidemiology of Aspergillus keratitis at a tertiary care eye hospital in South India and antifungal susceptibilities of the causative agents. Mycoses. 2013;56:26–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Thomas PA, Kaliamurthy J. Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect. 2013;19:210–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Jurkuna U, Behlau I, Colby K. Fungal keratitis: changing pathogens and risk factors. Cornea. 2009;28:638–43.CrossRefGoogle Scholar
  4. 4.
    Chen WL, Wu CY, Hu FR, et al. Therapeutic penetrating keratoplasty for microbial keratitis in Taiwan from 1987–2001. Am J Ophthalmol. 2004;137:736–43.PubMedGoogle Scholar
  5. 5.
    Tanure MA, Cohen EJ, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea. 2000;19:307–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003;16:730–97.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hedayati MT, Pasqualotto AC, Warn PA, et al. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology. 2007;153:1677–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheikhrouhou F, Makni F, Neji S, et al. Epidemiological profile of fungal keratitis in Sfax (Tunisia). J Mycol Med. 2014;24:308–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Al-Wathiqi F, Ahmad S, Khan Z. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait. BMC Infect Dis. 2013;13:126.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Samson RA, Visagie CM, Houbraken J, et al. Phylogeny, identification and nomenclature of the genus Aspergillus. Stud Mycol. 2014;78:141–73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gonçalves SS, Stchigel AM, Cano J, et al. In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi. Antimicrob Agents Chemother. 2013;57:1944–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tam EW, Chen JH, Lau EC, et al. Misidentification of Aspergillus nomius and Aspergillus tamarii as Aspergillus flavus: characterization by internal transcribed spacer, β-tubulin, and calmodulin gene sequencing, metabolic fingerprinting, and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2014;52:1153–60.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gonçalves SS, Cano JF, Stchigel AM, et al. Molecular phylogeny and phenotypic variability of clinical and environmental strains of Aspergillus flavus. Fungal Biol. 2012;116:1146–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Subcommittee on Antifungal Susceptibility Testing of the ESCMID. European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 2008;14:982–4.CrossRefGoogle Scholar
  15. 15.
    Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens. 2006;32:267–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Mehta H, Mehta HB, Garg P, et al. Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis. Indian J Ophthalmol. 2008;56:243–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sharma N, Agarwal P, Sinha R, et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series. Br J Ophthalmol. 2011;95:1735–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Prakash G, Sharma N, Goel M, et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol. 2008;146:56–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Lalitha P, Prajna NV, Kabra A, et al. Risk factors for treatment outcome in fungal keratitis. Ophthalmology. 2006;113:526–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Martins SA, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49:3402–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Iseli HP, Thiel MA, Hafezi F, et al. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Makdoumi K, Backman A, Mortensen J, et al. Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA). Graefes Arch Clin Exp Ophthalmol. 2010;248:207–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Said DG, Elalfy MS, Gatzioufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 2014;121:1377–82.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Elif Erdem
    • 1
  • Meltem Yagmur
    • 1
  • Hazal Boral
    • 2
  • Macit Ilkit
    • 2
  • Reha Ersoz
    • 1
  • Seyedmojtaba Seyedmousavi
    • 3
    • 4
    • 5
  1. 1.Department of Ophthalmology, Faculty of MedicineUniversity of ÇukurovaAdanaTurkey
  2. 2.Division of Mycology, Department of Microbiology, Faculty of MedicineUniversity of ÇukurovaAdanaTurkey
  3. 3.Department of Medical MicrobiologyRadboud UMCNijmegenThe Netherlands
  4. 4.Invasive Fungi Research CenterMazandaran University of Medical SciencesSariIran
  5. 5.Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations